Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 7686 results

  1. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409

    In development [GID-TA11508] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Iclepertin for treating cognitive impairment associated with schizophrenia ID6483

    Awaiting development [GID-TA11647] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  7. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  9. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 16 July 2025

    NICE guideline
    In development

  10. Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470

    In development [GID-TA11598] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Linaclotide acetate for treating Chronic idiopathic constipation [TS ID 12005]

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  13. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 22 May 2025

    Health technology evaluations
    In development